Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

In a study in pancreatic adenocarcinoma, the response rate of the combination of napabucasin with gemcitabine and nab-paclitaxel was close to 55%. This is promising, says Bekaii-Saab, as there is little response rate regularly seen in this disease.

More interestingly, the responses tended to be durable in most patients, with some approaching their second year of therapy.

View more from the 2017 World Congress on GI Cancer

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma